Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on January 02, 2018, 11:39:46 am
-
Individuals who have been previously treated for hepatitis C virus (HCV) do well on Gilead Sciences’ Vosevi (sofosbuvir/velpatasvir/voxilaprevir), even if they have virus with evidence of resistance to direct-acting antivirals (DAAs).
Researchers from the double-blind, randomized, placebo-controlled Phase III POLARIS-1 study conducted an analysis of Vosevi treatment among those who initially were randomized to receive a placebo and were subsequently offered 12 weeks of the actual study drug on an open-label basis, meaning they knew at that point that they were receiving Vosevi. The participants had all been previously treated with a DAA in the NS5A inhibitor class.
Read more...
https://www.hepmag.com/article/gileads-vosevi-works-among-treated-hep-c